Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic.
Saved in:
| Title: | Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. |
|---|---|
| Authors: | Souza JDS; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Zuardi AW; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil., Guimarães FS; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Osório FL; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil., Loureiro SR; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Campos AC; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Hallak JEC; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil., Dos Santos RG; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil., Machado Silveira IL; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Pereira-Lima K; University of Michigan Medical School, Ann Arbor, IN, United States.; Department of Psychiatry, Federal University of São Paulo, São Paulo, São Paulo, Brazil., Pacheco JC; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Ushirohira JM; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Ferreira RR; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Costa KCM; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Scomparin DS; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Scarante FF; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Pires-Dos-Santos I; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Mechoulam R; The Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel., Kapczinski F; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil.; Department of Psychiatry and Behavioural Neurosciences, McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.; Department of Psychiatry, Faculty of Medicine, Graduate Program in Psychiatry and Behavioral Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil., Fonseca BAL; Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Esposito DLA; Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Andraus MH; Chromatox Laboratory Ltd São Paulo, Brazil., Crippa JAS; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; National Institute for Science and Technology-Translational Medicine, Ribeirão Preto, Brazil. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2022 Oct 03; Vol. 13, pp. 856846. Date of Electronic Publication: 2022 Oct 03 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
